The 3rd CRISPR-Based Therapy Analytical Development Summit returns to Boston this September as the only industry-led meeting dedicated exclusively to analytical development for CRISPR-based therapeutics. As the race to the clinic accelerates, developers must deliver robust, regulatory-ready analytical packages to secure IND approval and demonstrate safety, efficacy, and product integrity to both regulators and investors.

With the FDA easing platform designation requirements and clinical milestones being reached across the field, from Beam Therapeutics’s proof-of-concept data to Arbor Biotherapeutics’ dual designations, analytical development has become a critical checkpoint. This summit unites analytical, QC, and regulatory leaders to explore cutting-edge tools for off-target detection, and to guide RNA validation, delivery analytics, and potency assay development.

Join experts from Beam, Mammoth, Excision, and KSQ Therapeutics to benchmark your strategy, gain actionable insights, and ensure your CRISPR programs are ready for regulatory progress and clinical success.